SPONSORED CONTENT
Rebates are nothing new in the prescription-drug market. What is new is their potential role in 340B. HRSA’s revised voluntary 340B Rebate Model Pilot represents a significant change in how covered entities (CEs) receive the economic benefit of 340B prices.
Traditionally, the 340B program has been an upfront discount model. Under the pilot, selected drugs will have to be purchased at WAC through existing distribution channels, with the 340B value delivered afterward as a manufacturer-funded rebate.
It sounds simple: pay first, get the 340B value back later. Operationally, that small change can create big ripple effects.
Eligible manufacturers must submit implementation plans by August 24. HRSA expects to make approvals, by September 24. Approved models may begin January 1, 2027. Manufacturers own the application deadline, but CEs will live with much of the operational reality.
Real Work Begins
The pilot may include up to twenty-five drugs from the first two cycles of the Medicare Drug Price Negotiation Program (MDPNP)—10 drugs with negotiated prices effective in 2026 and 15 additional drugs with negotiated prices effective in 2027. However, participation is limited to drugs that retain their status as CMS-selected drugs during the applicable negotiated-price period, as selected-drug status may terminate following CMS determinations in accordance with the MDPNP. The pilot applies only to specified NDC-11s for qualifying selected drugs, and manufacturer participation remains voluntary and subject to HHS approval.
The model is not just a Medicare workflow. CEs will need to identify eligible 340B use across commercial insurance, Medicare, Medicaid, and uninsured or cash-paying patients, spanning both pharmacy and medical claims.
HRSA establishes some guardrails. CEs must have at least forty-five calendar days from dispense to submit required information. After submission, manufacturers have ten calendar days to pay the rebate or issue a denial. The rebate is calculated at the unit level as WAC less the applicable 340B ceiling price on the date of dispense.
There is no single HRSA-designated technology platform. Participating manufacturers identify their proposed platforms and bear their cost of funding the platform. CEs must still be allowed to order through existing distribution mechanisms, including 340B wholesaler accounts with WAC pricing loaded.
The calculation may be straightforward. The hard part is everything around it: finding the right transaction, submitting it correctly, tracking the rebate, reconciling the payment, and resolving exceptions.
Real World Challenges
Working Capital. Paying WAC first means CEs will have to carry the difference until the rebate arrives. For higher-cost or higher-volume drugs, that can create meaningful cash-flow and wholesaler-credit pressure.
Payment. Ten days is fast, but incomplete submissions, denials, corrections, and resubmissions will happen. CEs need to know what was submitted, what should have been paid, what was actually paid, and what remains unresolved.
Medical Claims. Physician-administered drugs bring different billing conventions, units of measure, wastage, payer workflows, and reconciliation requirements. Pharmacy and medical claims may live in different systems, but the rebate workflow needs to connect them.
Maximum Fair Price (MFP) and 340B. Under the Medicare price negotiation law, drug companies are required to provide CEs the lower of MFP or the 340B price but not both discounts. he statutory nonduplication requirements make transaction-level visibility essential. Organizations need to understand which price applied, where payment flowed, and whether another rebate would create a duplicate discount.
Eligibility speed in a retrospective model, a delay in determining 340B eligibility can become a delay in recovering cash. Eligibility, accumulation, claims, payer data, submissions, payments, denials, and accounting records need to move together.
MFP Lessons
Since the MDPNP went live in January 2026, RxParadigm has supported several hospitals, health systems, clinics, community health centers, and pharmacies with MFP effectuation. The programs are not identical, but they share familiar mechanics: transaction identification, data exchange, retrospective payment, exception handling, disputes, and claim-level reconciliation that led to the following lessons:
Visibility. CEs commonly work across multiple TPAs, pharmacies, wholesalers, manufacturer systems, medical billing platforms, and financial systems. A manufacturer portal may manage one part of a rebate, but the CE must manage the entire transaction across all of them.
Automation Needs Experts. Automation helps, but expertise still matters. Eligibility validation, payment reconciliation, denial research, corrections, documentation, and escalation do not always fit neatly into an automated rule.
Dispute Workflows: Disputes need to be treated as workflow, not a fire drill. MFP has shown how quickly retrospective reimbursement can produce unpaid, underpaid, delayed, duplicated, or rejected transactions. CMS established complaint and dispute processes for MFP issues, subject to defined timelines. The 340B pilot similarly requires documented denials and provides pathways for challenge, HRSA involvement, and potentially the use of the Administrative Dispute Resolution process.
At scale, reconciliation and dispute management become core operating functions.
Rebate Readiness
CEs do not need to predict every manufacturer’s implementation approach. They do, however, need five essential capabilities:
- Submit rebate claims. Unlike the MFP reimbursement process, in which a pharmacy submits a claim once to facilitate payment, the 340B rebate model requires CEs to separately submit eligible claims to obtain rebate payments.
- Centralize data. Identify the systems containing eligibility, accumulation, pharmacy, medical, payer, reversal, and contract-pharmacy data, and establish a centralized data-management process.
- Track financial activity. Connect each eligible claim to its expected rebate, actual payment, remittance, denial, correction, reversal, or adjustment.
- Manage disputes. Establish clear ownership, aging rules, documentation requirements, escalation procedures, and a comprehensive audit trail.
- Consolidate reporting. Integrate reporting across manufacturers, TPAs, pharmacies, medical claims, MFP activity, and financial systems.
RxParadigm’s Tungsten+PLUS™ 340B Rebate Administration Platform draws on more than 25 years of rebate administration expertise, over five years of 340B clearinghouse development, and recent experience implementing MFP requirements. The platform provides end-to-end capabilities, including eligibility determination for pharmacy and medical claims, real-time pre-adjudication, automated data submission, claim-level reconciliation, dispute management, consolidated financial reporting, and coordinated wholesaler integration designed to help ease WAC-related working-capital pressures.
More Than a Rebate Portal
The objective is not to introduce another portal. It is to provide a connected, end-to-end transaction management platform that supports the entire rebate lifecycle—from eligibility determination and claim submission through payment reconciliation, dispute resolution, final financial settlement, and transparent financial reporting.
Under the new model, CEs must submit claims to receive rebates and manage every stage of the rebate lifecycle.
January 1 is not the finish line; it is when the real work begins. Every CE should be able to answer three fundamental questions: What are we owed? What have we received? What remains unresolved?
That is the true measure of rebate readiness.
Mesfin Tegenu is CEO and Chairman of RxParadigm. He can be reached at Mesfin.Tegenu@rxparadigm.com.
